Cargando…

Natural Negative Allosteric Modulators of 5-HT(3) Receptors

Chemotherapy-induced nausea and vomiting (CINV) remain the most common and devastating side-effects associated with cancer chemotherapy. In recent decades, several lines of research emphasize the importance of 5-hydroxytryptamine3 (5-HT(3;) serotonin) receptors in the pathogenesis and treatment of C...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Kury, Lina T., Mahgoub, Mohamed, Howarth, Frank Christopher, Oz, Murat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321066/
https://www.ncbi.nlm.nih.gov/pubmed/30513973
http://dx.doi.org/10.3390/molecules23123186
Descripción
Sumario:Chemotherapy-induced nausea and vomiting (CINV) remain the most common and devastating side-effects associated with cancer chemotherapy. In recent decades, several lines of research emphasize the importance of 5-hydroxytryptamine3 (5-HT(3;) serotonin) receptors in the pathogenesis and treatment of CINV. 5-HT(3) receptors are members of ligand-gated ion channels that mediate the rapid and transient membrane-depolarizing effect of 5-HT in the central and peripheral nervous system. These receptors play important roles in nausea and vomiting, as well as regulation of peristalsis and pain transmission. The development of antagonists for 5-HT(3) receptor dramatically improved the treatment of CINV in cancer patients. In fact, the most common use of 5-HT(3) receptor antagonists to date is the treatment of nausea and vomiting. In recent years, there has been an increasing tendency to use natural plant products as important therapeutic entities in the treatment of various diseases. In this article, we examined the results of earlier studies on the actions of natural compounds on the functional properties of 5-HT(3) receptors. It is likely that these natural modulators of 5-HT(3) receptors can be employed as lead structures for the synthesis of therapeutic agents for treating CINV in future clinical studies.